Celgene: Strong Quarter As Front-Line Myeloma Race Continues
This article was originally published in The Pink Sheet Daily
Executive Summary
Full-year results up, too, though Millennium’s priority-review Velcade looms.
You may also be interested in...
Millennium Earnings No Shocker, But How High Can Velcade Fly?
“In flux” myeloma space keeps analysts guessing.
Millennium Earnings No Shocker, But How High Can Velcade Fly?
“In flux” myeloma space keeps analysts guessing.
CHMP’s Revlimid Rebuff Will Have Limited Impact In EU Market
Analyst calls vote “more of a psychological setback” than anything, as drug already is approved on named-patient basis.